Takeda puts $120M in near-term cash on the table to complete a new oncology platform deal
Takeda is spending big to add a new piece to their oncology R&D puzzle.
This morning the global pharma company picked up an alliance with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
